# Obesity and Type 2 Diabetes

Excess adiposity is a central, modifiable driver of insulin resistance and type 2 diabetes progression. Management should integrate weight-directed treatment with complication-focused glucose-lowering therapy, prioritizing cardiometabolic outcomes, safety, treatment burden, and durable access.

**Clinical question:** How should clinicians assess and treat obesity to improve glycemia and cardiometabolic outcomes in adults with type 2 diabetes?

Updated: 2026-08-21T00:04:47.745086Z

## What matters in practice
- Treat obesity as a chronic cardiometabolic disease in type 2 diabetes; BMI identifies risk but does not distinguish adiposity from lean mass or characterize fat distribution. Add waist-based measures or body-composition assessment when BMI is less informative. [12]
- For type 2 diabetes with established ASCVD, heart failure, or CKD, choose glucose-lowering therapy for cardiorenal benefit irrespective of baseline HbA1c or metformin use. GLP-1 receptor agonists and SGLT2 inhibitors address different outcome priorities. [4]
- Tirzepatide and subcutaneous semaglutide provide the greatest weight-loss efficacy among diabetes therapies discussed in the supplied evidence; select according to clinical indication, contraindications, tolerability, cost, and access. [4]
- In heart failure, use SGLT2 inhibitors for established outcome benefit; semaglutide and tirzepatide improve symptoms and function in obesity-related HFpEF, whereas evidence in HFrEF remains insufficient and earlier liraglutide studies raised safety concerns. [10][12]
- Weight loss should trigger proactive reassessment of insulin, insulin secretagogues, antihypertensives, and diuretics to reduce hypoglycemia, hypotension, and volume depletion. [12]

## Assess adiposity, diabetes phenotype, and obesity-related complications

Move beyond a BMI-only assessment when it changes risk classification or treatment selection.

BMI remains a practical screening metric: U.S. obesity is conventionally BMI at least 30 kg/m², with class 1, 2, and 3 thresholds of 30 to less than 35, 35 to less than 40, and at least 40 kg/m², respectively. BMI is limited because it cannot distinguish fat from lean mass or fluid retention, and it does not characterize central adiposity. [12]

Measure waist circumference in addition to BMI when central adiposity or cardiometabolic risk classification is clinically uncertain. Thresholds cited by ACC are at least 35 inches in women and at least 40 inches in men; waist-to-height ratio of at least 0.50 is also abnormal. For many Asian populations, lower BMI and waist thresholds apply. [12]

The initial obesity-focused diabetes evaluation should identify treatment-relevant complications and contributors: ASCVD, HF phenotype, CKD and albuminuria, hypertension, dyslipidemia, sleep-disordered breathing, atrial fibrillation, MASLD, osteoarthritis, medication-associated weight gain, depression or eating disorder, food insecurity, and affordability barriers. Obesity and diabetes management should not be separated from prevention and treatment of these complications. [4][10][12]
- Document baseline weight, BMI, waist measure when useful, blood pressure, glycemic status, kidney function, lipid profile, current diabetes regimen, and weight-promoting medications. [4][12]
- For diabetes treatment selection, determine whether the patient has ASCVD/high ASCVD risk, HF, CKD, marked hyperglycemia, or a primary goal of weight loss. [4]
- Use person-first, nonstigmatizing language and shared decision-making; stigma may interfere with engagement and care delivery. [10][12]

*Adiposity measures that can alter clinical interpretation. [12]*

| Measure | Actionable interpretation | Key limitation |
| --- | --- | --- |
| BMI | Use for routine classification and medication eligibility; obesity is BMI ≥30 kg/m² in Europoid populations. [12] | Does not distinguish adiposity from muscle or fluid and does not quantify fat distribution. [12] |
| Waist circumference | Supports identification of central adiposity; abnormal at ≥35 inches in women or ≥40 inches in men in the cited U.S. thresholds. [12] | Can be distorted by fluid retention, particularly in HF. [10] |
| Waist-to-height ratio | A ratio ≥0.50 identifies abnormal central adiposity. [12] | Thresholds and implementation are less embedded in U.S. coverage and treatment pathways than BMI. [12] |
| DXA or other body-composition assessment | Consider when BMI is discordant with suspected excess adiposity, sarcopenia, or fluid-related weight change. [10][12] | Access, cost, and standardization limit routine use. [10] |

## Link adiposity treatment to diabetes and cardiovascular risk

The target is not weight alone; it is improvement in metabolic dysfunction and clinical outcomes.

Excess and dysfunctional adipose tissue promotes insulin resistance through ectopic lipid accumulation, altered adipokine signaling, inflammation, and impaired insulin action in liver and skeletal muscle; the practical consequence is progressive hyperglycemia and greater cardiometabolic risk. [23]

Weight loss as small as 5% is associated with improvement in blood pressure, triglycerides, fasting glucose, and incident diabetes risk; for people seeking improvement in weight-related comorbidities, ACC guidance identifies a practical target of at least 10% weight loss. [12]

In adults with type 2 diabetes, lifestyle intervention is foundational but should not be expected to replace evidence-based pharmacotherapy when cardiorenal risk, significant obesity, or treatment failure is present. In Look AHEAD, intensive lifestyle treatment did not reduce the primary cardiovascular composite outcome versus usual care, although participants achieving at least 10% loss in year 1 had lower cardiovascular event risk in post hoc analysis. [4]
- Favor glucose-lowering therapies with weight loss or weight-neutral effects when clinically feasible; GLP-1 receptor agonists and SGLT2 inhibitors reduce weight, whereas insulin, sulfonylureas, and thiazolidinediones promote weight gain. [4]
- Consider replacing nonessential weight-promoting drugs when a clinically appropriate alternative exists. [4][21]
- Prescribe aerobic and resistance activity for function, glycemia, and preservation of lean mass; exercise alone generally produces less weight loss than caloric restriction but improves functional status and supports maintenance. [10][21]

## Select diabetes therapy by cardiorenal risk and weight objective

Do not use a glucose-centric sequence when comorbidities determine outcome benefit.

For adults with type 2 diabetes and established ASCVD or indicators of high ASCVD risk, initiate a GLP-1 receptor agonist or SGLT2 inhibitor with demonstrated cardiovascular benefit regardless of HbA1c or background therapy. In cardiovascular outcomes trials, dulaglutide, liraglutide, subcutaneous semaglutide, canagliflozin, and empagliflozin reduced major adverse cardiovascular events versus placebo. [4]

For HF, SGLT2 inhibitors have consistent outcome benefit and should be prioritized. For CKD with eGFR below 60 mL/min/1.73 m² or albuminuria, SGLT2 inhibitors are preferred to slow CKD progression; current prescribing information described in the evidence allows initiation for kidney benefit at eGFR at least 20 mL/min/1.73 m², although glucose-lowering efficacy is substantially reduced below eGFR 45 mL/min/1.73 m². [4]

When obesity or weight-related complications are a major treatment target, tirzepatide and subcutaneous semaglutide have the highest weight-loss efficacy among the glucose-lowering options summarized in the supplied evidence. Metformin and DPP-4 inhibitors are generally weight neutral; SGLT2 inhibitors produce more modest weight loss. [4]
- Metformin remains useful for glycemic efficacy, low hypoglycemia risk, and cost, but current evidence does not support requiring metformin before a GLP-1 receptor agonist or SGLT2 inhibitor when cardiorenal indications are present. [4]
- Consider insulin for symptomatic or severe hyperglycemia, ketosis, catabolic weight loss, or HbA1c above 10%; once glucotoxicity improves, reassess whether insulin intensity can be reduced. [4]
- Before adding basal insulin in most patients, consider a GLP-1 receptor agonist because of similar glucose-lowering efficacy with less hypoglycemia and favorable weight effects. [4]

### Weight-directed incretin therapy

For chronic weight management, FDA-approved obesity formulations include liraglutide 3 mg daily, semaglutide 1.7 or 2.4 mg weekly, and tirzepatide 5, 10, or 15 mg weekly in eligible adults with obesity or overweight plus a weight-related comorbidity. In cited trials, mean weight loss was 8.0% with liraglutide, 14.9% with semaglutide, and up to 20.9% with tirzepatide at maximum dose. [12]

Dose escalation is designed to reduce gastrointestinal intolerance. Semaglutide starts at 0.25 mg subcutaneously weekly and is increased every 4 weeks to 1.7 or 2.4 mg. Tirzepatide starts at 2.5 mg subcutaneously weekly and is increased every 4 weeks to a maintenance dose of 5, 10, or 15 mg. [12]
- Avoid GLP-1–based therapies in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2; hypersensitivity is also a contraindication. [12]
- Use caution with prior pancreatitis, gallbladder disease, diabetic retinopathy, insulin-treated diabetes, and volume-sensitive CKD or HF. [4][10][12]
- Expect nausea, vomiting, diarrhea, constipation, and reduced appetite; reduce to a previously tolerated dose if adverse effects persist. [12]
- Do not use compounded incretin products when FDA-approved products are available; ACC discourages compounded products because of dosing errors, counterfeit products, and impurity concerns. [12]

*Medication selection for type 2 diabetes with obesity. [4][12]*

| Clinical priority | Preferred treatment direction | Important implementation point |
| --- | --- | --- |
| Established ASCVD or high ASCVD risk | GLP-1 receptor agonist or SGLT2 inhibitor with demonstrated cardiovascular benefit. [4] | Use independent of HbA1c or metformin exposure when indicated. [4] |
| Heart failure | SGLT2 inhibitor with demonstrated HF benefit. [4] | Monitor volume status and consider diuretic adjustment, especially during intercurrent illness or gastrointestinal adverse effects. [4][12] |
| CKD or albuminuria | SGLT2 inhibitor preferred; GLP-1 receptor agonist is a reasonable alternative when SGLT2 inhibitor cannot be used. [4] | Initiation for kidney benefit is described at eGFR ≥20 mL/min/1.73 m²; glycemic efficacy declines below eGFR 45 mL/min/1.73 m². [4] |
| Primary weight-loss objective | Tirzepatide or subcutaneous semaglutide generally provide greatest weight loss. [4][12] | Use obesity-indicated formulations and titration schedules when treating obesity. [12] |
| Marked symptomatic hyperglycemia or catabolism | Insulin, with or without GLP-1 receptor agonist. [4] | Reassess for deintensification after control improves to avoid excess weight gain and hypoglycemia. [4] |

## Monitor for hypoglycemia, volume depletion, and treatment-specific adverse effects

The highest-yield safety action is active medication deintensification during weight loss.

When initiating incretin-based weight therapy in diabetes, reassess insulin and insulin secretagogues to prevent hypoglycemia. In patients with HF or hypertension, reassess diuretics and antihypertensives during dose escalation and clinically meaningful weight loss to avoid intravascular depletion or hypotension. [10][12]

SGLT2 inhibitors are associated with diabetic ketoacidosis, including euglycemic presentations. In type 2 diabetes, discontinue the SGLT2 inhibitor when ketoacidosis is suspected and hold it 3 to 4 days before scheduled surgery, during prolonged fasting or very low carbohydrate intake, and during critical illness. [4]

Monitor symptoms rather than serial lipase concentrations for pancreatitis. If pancreatitis develops while receiving a GLP-1 receptor agonist, DPP-4 inhibitor, or tirzepatide, discontinue therapy and do not restart it. [4]
- At initiation and each titration contact: weight, glycemic data, gastrointestinal tolerance, hydration, blood pressure, hypoglycemia, and adherence/access. [12]
- In patients with HF, CKD, diuretic use, or significant gastrointestinal symptoms: recheck kidney function and electrolytes as clinically indicated during early incretin dose escalation. [10]
- With semaglutide in pre-existing diabetic retinopathy, arrange close retinal surveillance; rapid HbA1c reduction may contribute to early worsening. [4]
- Monitor for gallbladder symptoms; GLP-1–based therapies are associated with increased gallbladder and biliary disease risk. [4][12]

## Use phenotype-specific evidence for heart failure and metabolic procedures

Intentional weight loss is clinically useful, but the evidence base differs substantially by HF phenotype and intervention.

In obesity-related HFpEF, semaglutide and tirzepatide have randomized evidence for improved symptoms and functional capacity. In STEP-HFpEF, semaglutide improved Kansas City Cardiomyopathy Questionnaire clinical summary score and 6-minute walk distance; in SUMMIT, tirzepatide reduced the composite of cardiovascular death or worsening HF. [10][12]

Do not extrapolate HFpEF incretin evidence to HFrEF. Earlier liraglutide trials in advanced HFrEF raised concern for HF hospitalization and arrhythmias, while larger cardiovascular outcomes studies have not demonstrated clear harm; safety and efficacy of modern anti-obesity incretin therapy in HFrEF remain uncertain. [10]

Metabolic and bariatric surgery produces larger and more durable weight loss than lifestyle therapy or pharmacotherapy, but established HF increases perioperative risk. Observational data suggest fewer HF events after surgery, yet randomized outcomes trials in established HF are lacking; optimize HF therapy and refer to experienced multidisciplinary centers. [10]
- For metabolic surgery, the cited ASMBS/IFSO indications include BMI at least 35 kg/m², or BMI 30 to 34.9 kg/m² with metabolic disease. [10]
- In HF, stabilize volume status and guideline-directed therapy before procedural referral; postoperative risks include MI, pulmonary edema, atrial fibrillation, AKI, respiratory failure, and sepsis. [10]
- Protect lean mass during pharmacologic or procedural weight loss with nutritional and resistance-training strategies, particularly in older adults or patients with frailty. [10][12]

## Common questions

### Should metformin be required before starting a GLP-1 receptor agonist or SGLT2 inhibitor?

No when cardiorenal indications drive treatment. GLP-1 receptor agonists or SGLT2 inhibitors with demonstrated benefit may be initiated for ASCVD, HF, or CKD independent of HbA1c and background metformin use. [4]

### Which diabetes medications are most useful when obesity is the dominant treatment target?

Tirzepatide and subcutaneous semaglutide provide the greatest weight-loss efficacy in the supplied evidence. SGLT2 inhibitors provide more modest loss but may be preferred for HF or CKD outcome benefit. [4][12]

### When should an SGLT2 inhibitor be held?

Hold SGLT2 inhibitors 3 to 4 days before scheduled surgery and during prolonged fasting, very low carbohydrate intake, or critical illness because of ketoacidosis risk; discontinue promptly if ketoacidosis is suspected. [4]

### Are GLP-1-based therapies appropriate in HFrEF?

Evidence is insufficient. HFpEF data support symptom and functional benefit, but earlier liraglutide studies in advanced HFrEF raised safety concerns; use individualized specialist-informed decision-making. [10]

### What weight-loss target should be discussed with a patient with type 2 diabetes?

An initial target of at least 5% is associated with improvement in glycemic and cardiometabolic measures; at least 10% is a practical target when attempting to improve weight-related comorbidities. [12]

## References
1. WHO Guideline on GLP-1 Therapies for Obesity in Adults — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/2842199
2. Utility of current obesity thresholds in signaling diabetes ... — drc.bmj.com — https://drc.bmj.com/content/3/1/e000114
3. Type 2 diabetes in adults - History and exam — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/24/history-exam
4. Advances in the management of type 2 diabetes in adults — bmjmedicine.bmj.com — https://bmjmedicine.bmj.com/content/2/1/e000372
5. Type 2 diabetes in adults - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/24
6. Obesity in children - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/1085?locale=zh_CN
7. Association of body indices and risk of mortality in patients ... — drc.bmj.com — https://drc.bmj.com/content/11/4/e003474
8. Lifetime risk to progress from pre-diabetes to type 2 ... — drc.bmj.com — https://drc.bmj.com/content/8/2/e001529
9. Obesity Management in Adults: A Review | Bariatric Surgery — jamanetwork.com — https://jamanetwork.com/journals/jama/article-abstract/2812316
10. 2025 ACC Scientific Statement on the Management of ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.05.008
11. Long-Term Impact of Clinical Obesity on Heart Failure Development and Prognosis: New Insights — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacasi.2026.01.031
12. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health: A Report of the American College of Cardiology Solution Set Oversight Committee — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.05.024
13. important role of comorbidities in the management of obesity — academic.oup.com — https://academic.oup.com/jes/article/10/3/bvag012/8430946
14. Screening for Type 2 Diabetes and Dysglycemia — academic.oup.com — https://academic.oup.com/epirev/article/33/1/63/483202
15. Risk Factors for Progression to Type 2 Diabetes in a Pediatric ... — academic.oup.com — https://academic.oup.com/jes/article/7/11/bvad118/7300968
16. Body Mass Index and Diabetes Incidence Across the Adult ... — academic.oup.com — https://academic.oup.com/jes/article/8/11/bvae156/7749601
17. Obesity management in primary care: A joint clinical perspective and expert review from the Obesity Medicine Association (OMA) and the American College of Osteopathic Family Physicians (ACOFP) - 2025 — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2667368125000166
18. Obesity Management - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/obesity-management
19. Obesity Management - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/obesity-management
20. Surgical and interventional approaches for the treatment of ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1933287425005069
21. Diagnosis and Non-Invasive Treatment of Obesity in Adults with Type 2 Diabetes Mellitus: A Review of Guidelines — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10342979
22. Executive Summary - Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK2008
23. The Role of Obesity in Type 2 Diabetes Mellitus—An Overview — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10855901
24. Treatment of Obesity in Patients With Diabetes - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5687113

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.